N-Methyltryptamine

N-Methyltryptamine at a Glance

N-methyltryptamine (NMT) is one of the simplest tryptamines — the parent indole amine tryptamine carrying a single methyl group on its side-chain nitrogen. It sits one step along the biosynthetic methylation ladder that runs from tryptamine → NMT → N,N-dimethyltryptamine (DMT), the successive N-methylations catalysed by the enzyme indolethylamine N-methyltransferase (INMT) ^{2,3Reference 2Mack JP et al. · 1988N,N-Dimethyltryptamine production in Phalaris aquatica seedlings: a mathematical model for its synthesisView study →Reference 3Glynos NG et al. · 2023AnimalIndolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in ratsView study →}.

It is found as a minor alkaloid in several plants used as tryptamine sources — Acacia confusa, jurema (Mimosa tenuiflora), Illinois bundleflower (Desmanthus illinoensis) and Phalaris grasses — and is also present in mammals, including humans, as an endogenous trace amine ^{1,2,6Reference 1Buchanan MS et al. · 2007NMR spectral assignments of a new chlorotryptamine alkaloid and its analogues from Acacia confusaView study →Reference 2Mack JP et al. · 1988N,N-Dimethyltryptamine production in Phalaris aquatica seedlings: a mathematical model for its synthesisView study →Reference 6Khan MZ · 2016The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in the central nervous systemView study →}.

The honest framing for this molecule is narrow. NMT is not a recreational psychedelic: it is a substrate of monoamine oxidase (MAO), rapidly broken down before it can reach the brain in quantity, and it is not orally psychoactive on its own and only weakly active at best ^{4,5Reference 4Kärkkäinen J et al. · 2005Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissuesView study →Reference 5Nichols DE · 2018N,N-dimethyltryptamine and the pineal gland: separating fact from mythView study →}. Its interest is almost entirely as a biosynthetic precursor to DMT and as a trace amine acting on trace-amine-associated receptor 1 (TAAR1) ^{6,7Reference 6Khan MZ · 2016The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in the central nervous systemView study →Reference 7Bunzow JR et al. · 2001AnimalAmphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptorView study →}. Human research on NMT specifically is very thin.

The Methylation Ladder

The single feature that defines this molecule is its position in a two-step N-methylation sequence. Starting from the amino acid tryptophan, plants and animals decarboxylate it to tryptamine; a first N-methylation gives N-methyltryptamine; a second gives N,N-dimethyltryptamine ^{2Reference 2Mack JP et al. · 1988N,N-Dimethyltryptamine production in Phalaris aquatica seedlings: a mathematical model for its synthesisView study →}. In Phalaris seedlings this was resolved enzymatically: tryptophan decarboxylase plus two N-methyl-transferase activities together account for DMT synthesis, with NMT as the obligatory mono-methylated intermediate ^{2Reference 2Mack JP et al. · 1988N,N-Dimethyltryptamine production in Phalaris aquatica seedlings: a mathematical model for its synthesisView study →}.

In mammals the same ladder is attributed to indolethylamine N-methyltransferase (INMT), which methylates tryptamine (and the 5-hydroxy series, serotonin → bufotenin) using S-adenosyl-methionine as the methyl donor ^{3,4Reference 3Glynos NG et al. · 2023AnimalIndolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in ratsView study →Reference 4Kärkkäinen J et al. · 2005Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissuesView study →}. The picture is not fully settled: INMT-knockout rats retain tryptamine-dependent methylation activity in brain and lung, implying that other enzymes can also carry out the reaction ^{3Reference 3Glynos NG et al. · 2023AnimalIndolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in ratsView study →}.

The practical consequence of being a mid-ladder intermediate is that NMT rarely accumulates. It is either methylated onward to DMT or degraded, which is part of why it is usually a minor constituent and a trace amine rather than a stored end-product.

What It's Used For

There is no body of clinical or applied research on N-methyltryptamine as a substance in its own right, so there is no meaningful “evidence by application” to rank. What exists is mechanistic and biochemical: where NMT sits in tryptamine metabolism, what receptor family it belongs to, and why it is not orally active. The sections below state that directly.

Mechanisms

The load-bearing rows are the first two: NMT is defined by being a substrate — of INMT (which makes and consumes it) and of MAO (which clears it). Its status as a trace amine and its structural kinship to serotonin place it in the family, but do not make it a psychoactive drug.

Pharmacokinetics

The decisive pharmacokinetic fact is that NMT, like tryptamine itself, is a monoamine-oxidase substrate and is degraded rapidly. Endogenous methylated tryptamines are detectable only in minute quantities in blood and tissue and turn over quickly ^{4,5Reference 4Kärkkäinen J et al. · 2005Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissuesView study →Reference 5Nichols DE · 2018N,N-dimethyltryptamine and the pineal gland: separating fact from mythView study →}; the same rapid MAO-mediated clearance that keeps endogenous DMT sub-psychoactive applies to its mono-methyl precursor ^{5Reference 5Nichols DE · 2018N,N-dimethyltryptamine and the pineal gland: separating fact from mythView study →}.

Taken by mouth without MAO inhibition, NMT would be expected to be extensively first-pass metabolised and not to reach the brain in psychoactive amounts — consistent with its reputation as, at most, only weakly active. No formal human bioavailability, half-life or metabolite dataset for isolated NMT has been characterised.

Clinical Trials

No clinical trials of N-methyltryptamine have been conducted. The molecule appears in the literature as a plant alkaloid, a biosynthetic intermediate and an endogenous trace amine, not as an investigational agent.

Last checked: July 2026.

Isolate vs. Plant Studies

Almost nothing about NMT rests on the isolated molecule being tested for an effect. The plant work that names it is phytochemical — identifying and quantifying NMT as one alkaloid among several in Acacia confusa, jurema and related species ^{1Reference 1Buchanan MS et al. · 2007NMR spectral assignments of a new chlorotryptamine alkaloid and its analogues from Acacia confusaView study →} — not pharmacological. The animal work is enzymatic, tracing NMT’s place in tryptamine methylation ^{2,3Reference 2Mack JP et al. · 1988N,N-Dimethyltryptamine production in Phalaris aquatica seedlings: a mathematical model for its synthesisView study →Reference 3Glynos NG et al. · 2023AnimalIndolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in ratsView study →}. Where NMT is discussed as potentially psychoactive, that discussion is by analogy to DMT and is undercut by its MAO susceptibility rather than supported by isolate trials ^{5Reference 5Nichols DE · 2018N,N-dimethyltryptamine and the pineal gland: separating fact from mythView study →}. In short, there is no isolate-versus-plant efficacy comparison to make, because neither the isolate nor the plant has been studied for a therapeutic effect attributable to NMT.

Prevalence in Nature

N-methyltryptamine is a minor and inconsistent constituent rather than a signature compound of any one plant. It has been isolated from the bark of Acacia confusa, alongside other tryptamine alkaloids ^{1Reference 1Buchanan MS et al. · 2007NMR spectral assignments of a new chlorotryptamine alkaloid and its analogues from Acacia confusaView study →}, and is reported among the tryptamines of jurema (Mimosa tenuiflora), Illinois bundleflower (Desmanthus illinoensis) and Phalaris grasses — the same taxa cultivated or foraged as sources of DMT, in which NMT appears as the accompanying mono-methylated intermediate ^{2Reference 2Mack JP et al. · 1988N,N-Dimethyltryptamine production in Phalaris aquatica seedlings: a mathematical model for its synthesisView study →}. Because it is a mid-pathway intermediate, its concentration tends to be low and variable, shifting with species, plant part, provenance and growth stage; published quantitative figures for NMT specifically are sparse.

It is not confined to plants. As an endogenous trace amine, NMT (with tryptamine, DMT and bufotenin) occurs in mammalian tissue in trace quantities, formed in situ by N-methylation of tryptamine ^{3,4,6Reference 3Glynos NG et al. · 2023AnimalIndolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in ratsView study →Reference 4Kärkkäinen J et al. · 2005Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissuesView study →Reference 6Khan MZ · 2016The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in the central nervous systemView study →}. These endogenous levels are very low and their physiological role remains uncertain.

Discovery & Synthesis

N-methyltryptamine was characterised as a plant tryptamine alkaloid over the mid-twentieth-century period of indole-alkaloid surveys of Acacia, Mimosa, Desmanthus and Phalaris, and was recognised in parallel as an endogenous trace amine and as the mono-N-methyl intermediate in the biosynthesis of DMT — the reaction sequence later mapped enzymatically in Phalaris seedlings ^{2Reference 2Mack JP et al. · 1988N,N-Dimethyltryptamine production in Phalaris aquatica seedlings: a mathematical model for its synthesisView study →} and attributed in mammals to INMT ^{3,4Reference 3Glynos NG et al. · 2023AnimalIndolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in ratsView study →Reference 4Kärkkäinen J et al. · 2005Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissuesView study →}. Its name is purely descriptive: tryptamine bearing one (N-methyl) group on the side-chain nitrogen.

Synthetically, NMT is a straightforward mono-N-methyl tryptamine and arises as an intermediate or by-product in tryptamine methylation chemistry; analyses of amateur DMT syntheses, for example, report mixed mono- and di-methylated and quaternary products rather than clean DMT, which is where compounds of this class surface incidentally ^{8Reference 8Martins CPB et al. · 2009Characterisation of a proposed internet synthesis of N,N-dimethyltryptamine using liquid chromatography/electrospray ionisation tandem mass spectrometryView study →}. It is not manufactured as a commercial product in its own right.

Patents: not yet researched.

Toxicity & Safety

N-methyltryptamine carries a low toxicity flag. It is an endogenous trace amine and a monoamine-oxidase substrate, cleared rapidly under normal conditions, and there is no evidence base indicating that isolated NMT is acutely hazardous at the trace levels at which it naturally occurs. There is, equally, no dedicated isolate toxicology dataset — no characterised repeat-dose, genotoxicity or reproductive-toxicity package — so the low rating reflects the absence of a known hazard signal for a trace amine, not a positive demonstration of safety.

The one safety consideration that follows directly from its biochemistry is the trace-amine / MAO-inhibitor interaction. Because NMT is normally kept low by MAO, inhibiting that enzyme (with a pharmaceutical MAOI or with β-carboline-rich preparations such as those built around harmine) removes the brake that clears trace amines — the same principle that makes dietary tyramine hazardous with MAOIs, and the same principle that makes DMT orally active in ayahuasca. This is a class caution about combining trace-amine-containing material with MAO inhibition, stated here as biochemistry rather than as use guidance.

Safety at a Glance

✅ Low / no toxicity

• Endogenous trace amine, rapidly metabolised. Occurs naturally at trace levels and is cleared by monoamine oxidase; no known hazard signal at those levels.
• MAO-inhibitor interaction (class caution). MAO inhibition removes the enzyme that normally clears trace amines, so combining trace-amine-bearing material with an MAOI changes its pharmacology — the tyramine/ayahuasca principle.
• No isolate toxicology dataset. No characterised repeat-dose, genotoxicity or reproductive-toxicity data exist for the pure compound; low is the absence of a signal, not a safety demonstration.

Dosage

There is no established or recommended dose for N-methyltryptamine. It is not used as a stand-alone substance: it is not orally psychoactive on its own, is a monoamine-oxidase substrate, and is of interest as a biosynthetic precursor and endogenous trace amine rather than as a preparation to be taken. No research dosing figures for isolated NMT exist to report. This is a statement of fact about the molecule, not a personal recommendation.

References

1. Buchanan MS, Carroll AR, Pass D, Quinn RJ (2007). NMR spectral assignments of a new chlorotryptamine alkaloid and its analogues from Acacia confusa. Magnetic Resonance in Chemistry. https://pubmed.ncbi.nlm.nih.gov/17310474/
2. Mack JP, Mulvena DP, Slaytor M (1988). N,N-Dimethyltryptamine production in Phalaris aquatica seedlings: a mathematical model for its synthesis. Plant Physiology. https://pubmed.ncbi.nlm.nih.gov/16666301/
3. Glynos NG, Carter L, Lee SJ, et al. (2023). Indolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in rats. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/36609666/
4. Kärkkäinen J, Forsström T, Tornaeus J, et al. (2005). Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues. Scandinavian Journal of Clinical and Laboratory Investigation. https://pubmed.ncbi.nlm.nih.gov/16095048/
5. Nichols DE (2018). N,N-dimethyltryptamine and the pineal gland: separating fact from myth. Journal of Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/29095071/
6. Khan MZ, Nawaz W (2016). The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in the central nervous system. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/27424325/
7. Bunzow JR, Sonders MS, Arttamangkul S, et al. (2001). Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Molecular Pharmacology. https://pubmed.ncbi.nlm.nih.gov/11723224/
8. Martins CPB, Freeman S, Alder JF, Brandt SD (2009). Characterisation of a proposed internet synthesis of N,N-dimethyltryptamine using liquid chromatography/electrospray ionisation tandem mass spectrometry. Journal of Chromatography A. https://pubmed.ncbi.nlm.nih.gov/19592003/

View all 8 references▾